Close Menu

myelodysplastic syndrome

The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.

Patients with two copies of mutant TP53 had worse survival and treatment response compared to patients with one copy who had similar outcomes to those with wildtype TP53.

Of the eight patients who received drugs recommended by the tumor board based on data from the drug sensitivity assay, 75 percent responded.

The drug, which is designed to restore normal functioning of p53, has allowed a promising proportion of TP53-mutated MDS patients to receive stem cell transplants in early trials.

Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.

The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.